Insider Trading Activity For Galectin Therapeutics Inc (NASDAQ:GALT)
Kevin D Freeman , Director of Galectin Therapeutics Inc (NASDAQ:GALT) reportedly Bought 2,000 shares of the company’s stock at an average price of 4.1 for a total transaction amount of $8,200.00 SEC Form
Insider Trading History For Galectin Therapeutics Inc (NASDAQ:GALT)
On 10/8/2012 Peter G Traber, CEO, bought 5,000 with an average share price of $2.07 per share and the total transaction amounting to $10,350.00.
On 10/9/2012 Peter G Traber, CEO, bought 2,500 with an average share price of $2.00 per share and the total transaction amounting to $5,000.00.
On 10/12/2012 Peter G Traber, CEO, bought 2,500 with an average share price of $2.11 per share and the total transaction amounting to $5,275.00.
On 5/28/2013 Kevin D Freeman, Director, bought 1,000 with an average share price of $4.21 per share and the total transaction amounting to $4,210.00.
On 6/3/2013 John F Mauldin, Director, bought 1,176 with an average share price of $4.21 per share and the total transaction amounting to $4,950.96.
On 11/15/2013 James C Czirr, Chairman, bought 1,000 with an average share price of $6.90 per share and the total transaction amounting to $6,900.00.
On 11/18/2013 Peter G Traber, CEO, bought 1,000 with an average share price of $5.80 per share and the total transaction amounting to $5,800.00.
Analyst Ratings History For Galectin Therapeutics Inc (NASDAQ:GALT)
- On 4/3/2017 FBR & Co Reiterated Rating Market Perform with a price target of $2.00
- On 10/6/2017 Seaport Global Securities Reiterated Rating Buy with a price target of $5.00
- On 12/7/2017 HC Wainwright Reiterated Rating Buy with a price target of $6.00 to $10.00
- On 1/4/2018 Roth Capital Boost Price Target of rating Buy with a price target of $3.00 to $8.00
Recent Trading Activity for Galectin Therapeutics Inc (NASDAQ:GALT)
Shares of Galectin Therapeutics Inc closed the previous trading session at with 4.289999961853027 shares trading hands.